Skip to main content

Table 1 Pharmacokinetics of cotrimoxazole (TMP/SMX) in various non-critically ill populations with normal renal and liver function

From: Cotrimoxazole - optimal dosing in the critically ill

Population [Reference]

Gender

Age (year)

Weight (kg)

Dose

Route

Duration

Cmax mcg/ml

Tmax (min)

Cmin mcg/ml

Vd (Liters/kg)

T1/2 (hours)

Clearance (ml/min/kg)

Normal [8]

1 F/3 M

34

66

80 mg TMP

PO

Q12h × 9 days

   

1.5

8.2

 
    

400 mg SMX

    

0.26

9.8

 

Normal [9]

N/A

21 to 40

N/A

240 mg TMP

IV

Q12h × 7 doses

5.91

15

2.64

 

16.5

 
    

1,200 mg SMX

 

178

 

78

 

14.1

 

Normal [7]

12 M

28

75.8

20.2 mg/kg/day TMP

PO

Q6h × 13 doses

13.6

114

 

1.4

13.6

1.05

    

101.1 mg/kg/day SMX

 

372

156

 

0.25

14.0

0.024

Normal [6]

6 M

26.7

73.7

12.6 mg/kg/day TMP

PO

Q6h × 3 days

8.3

90

6.1

1.78

14.6

0.89

    

63.3 mg/kg/day SMX

 

247

108

199

0.27

14.0

0.02

HIV PCP [10]

1 F/22 M

24 to 75

59

15 to 22 mg/kg TMP

IV (15)

Q6h × 4 to 6 days

  

7.7

   
    

75 to 110 mg/kg SMX

PO (8)

  

198

   

PCP [2]

N/A

37

67.6

16.1 mg/kg/day TMP

IV

Q6 to 8 h × 2 to 10 days

7.9

15

 

1.5

11.3

1.73

    

80.5 mg/kg/day SMX

 

186

  

0.4

14.3

0.34

Ventilated

N/A

37

68.5

14.7 mg/kg/day TMP

IV

Q6 to 8 h × 2 to 10 days

8.1

15

 

1.6

10.9

1.88

PCP [2]

   

73.4 mg/kg/day SMX

 

163

  

0.5

15.5

0.40

Oncology [11]

N/A

N/A

N/A

150 mg/m2 TMP

IV

Q8h × 24 hours

7.02

65

3.65

 

9.60

 
    

750 mg/m2 SMX

 

148

 

88

 

10.7

 

Infected

6 F/5 M

60

65

160 mg TMP

IV

Q8h × 4 days

8.8

60

5.6

0.72

11.3

1.13

Cancer [12]

   

800 SMX

 

105.6

 

70.6

0.27

12.8

0.04

Trauma [3]

2 F/13 M

31

87

8 mg/kg/day TMP

IV

Q12h

   

2.1

9.8

2.8

    

40 mg/kg/day SMX

    

0.51

8.4

0.75

  1. M, male; F, female; Cmax, maximum concentration within the dosing interval; Tmax, time to reach maximum concentration; Cmin, minimum concentration within dosing interval.
  2. Vd, volume of distribution; T1/2, calculated half-life; N/A, not available; PO, oral administration; IV, intravenous administration; PCP, Pneumocystis jovenii pneumonitis.